Today: Nov 21, 2024
RU / EN
Last update: Oct 30, 2024
Home page → All issues → Volume 9, Issue 3 (2017) → Article details
Pathomorphism of Limb Major Vessels in Experimental Atherogenic Inflammation. The Role of Adventitial Intimal Relations (Review)

Pathomorphism of Limb Major Vessels in Experimental Atherogenic Inflammation. The Role of Adventitial Intimal Relations (Review)

Kirichenko А.К., Patlataya N.N., Sharkova А.F., Pevnev А.А., Kontorev К.V., Shapovalova О.V., Gorban М.Е., Bolshakov I.N.
Key words: atherogenic inflammation; atherogenesis markers; vascular wall; therapeutic angiogenesis; morphological angioplasty; genetically engineered drugs; biodegradable polysaccharide structures; vascular adventitia engineering.
2017, volume 9, issue 3, page 162.
DOI: https://doi.org/10.17691/stm2017.9.3.20

Full text

html pdf
1901
1833

The review considers the problems of pathological destruction of a vascular wall at early signs of atherogenic inflammation of major arteries in hyperlipidemia in relation to modern technologies of local angioplasty. It has shown the role of molecular markers in atherogenic inflammation development and progression in intima and subintimal space. The emphasis is laid on modern genetically engineered and biopolymer technologies for vascular wall repair, the significance of adventitial and para-adventitial arterial layers in atherogenic inflammation, the formation of a therapeutic angiogenesis effect when using modern methods of adventitia bioengineering.

  1. European Stroke Organisation, Tendera M., Aboyans V., Bartelink M.L., Baumgartner I., Clément D., Collet J.P., Cremonesi A., De Carlo M., Erbel R., Fowkes F.G., Heras M., Kownator S., Minar E., Ostergren J., Poldermans D., Riambau V., Roffi M., Röther J., Sievert H., van Sambeek M., Zeller T.; ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32(22): 2851–2906, https://doi.org/10.1093/eurheartj/ehr211.
  2. Olin J.W., Sealove B.A. Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc 2010; 85(7): 678–692, https://doi.org/10.4065/mcp.2010.0133.
  3. Writing Committee to Develop Clinical Data Standards for Peripheral Atherosclerotic Vascular Disease, Creager M.A., Belkin M., Bluth E.I., Casey D.E. Jr., Chaturvedi S., Dake M.D., Fleg J.L., Hirsch A.T., Jaff M.R., Kern J.A., Malenka D.J., Martin E.T., Mohler E.R. 3rd, Murphy T., Olin J.W., Regensteiner J.G., Rosenwasser R.H., Sheehan P., Stewart K.J., Treat-Jacobson D., Upchurch G.R. Jr., White C.J., Ziffer J.A., Hendel R.C., Bozkurt B., Fonarow G.C., Jacobs J.P., Peterson P.N., Roger V.L., Smith E.E., Tcheng J.E., Wang T., Weintraub W.S. 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Peripheral Atherosclerotic Vascular Disease). Circulation 2012; 125(2): 395–467, https://doi.org/10.1161/cir.0b013e31823299a1.
  4. Fowkes F.G., Rudan D., Rudan I., Aboyans V., Denenberg J.O., McDermott M.M., Norman P.E., Sampson U.K., Williams L.J., Mensah G.A., Criqui M.H. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382(9901): 1329–1340, https://doi.org/10.1016/s0140-6736(13)61249-0.
  5. Schanzer A., Conte M.S. Critical limb ischemia. Curr Treat Options Cardiovasc Med 2010; 12(3): 214–229, https://doi.org/10.1007/s11936-010-0076-7.
  6. Baumgartner I. Peripheral artery occlusive disease a major contributor to cardiovascular public health burden. Eur Heart J 2015; 36(15): 894–896, https://doi.org/10.1093/eurheartj/ehu438.
  7. Reinecke H., Unrath M., Freisinger E., Bunzemeier H., Meyborg M., Lüders F., Gebauer K., Roeder N., Berger K., Malyar N.M. Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. Eur Heart J 2015; 36(15): 932–938, https://doi.org/10.1093/eurheartj/ehv006.
  8. Nehler M.R., Duval S., Diao L., Annex B.H., Hiatt W.R., Rogers K., Zakharyan A., Hirsch A.T. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg 2014; 60(3): 686–695.e2, https://doi.org/10.1016/j.jvs.2014.03.290.
  9. Gulati A., Garcia L., Acharji S. Epidemiology of chronic critical limb ischemia. In: Critical limb ischemia. Springer International Publishing; 2016; p. 9–14, https://doi.org/10.1007/978-3-319-31991-9_2.
  10. Karpov Yu.A., Sorokin E.V. Intensive medical treatment of patients with atherosclerosis. Kardiologiya 2005; 45(8): 4–7.
  11. Bolshakov I.N., Dolgikh O.A., Kirichenko A.K., Kotikov A.R., Gorbunova V.O. Lipid spectrum and microcirculation when using biopolymers in an atherogenesis model. Fundamental’nye issledovaniya 2009; S7: 41–42.
  12. Bolshakov I.N., Shestakova L.A., Kotikov A.R., Kaptyuk G.I. The experimental atherosclerotic inflammation of the main arteries in rabbits. Low traumatic technology of morphological reconstruction of the vascular wall at the early atherosclerotic stages. Fundamental’nye issledovaniya 2013; 8–2: 343–350.
  13. Bolshakov I.N., Shestakova L.A., Kotikov A.R., Kaptyuk G.I. Experimental atherosclerosis in rats. Morphological reconstruction of the main artery wall with the polyssacharide biopolymers. Fundamental’nye issledovaniya 2013; 10–3: 557–563.
  14. Alimohammadi M., Pichardo-Almarza C., Agu O., Díaz-Zuccarini V. A multiscale modelling approach to understand atherosclerosis formation: а patient-specific case study in the aortic bifurcation. Proc Inst Mech Eng H 2017; 231(5): 378–390, http s://doi.org/10 .1177/0954411917697356.
  15. Steinman D.A. Image-based computational fluid dynamics: a new paradigm for monitoring hemodynamics and atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2004; 4(2): 183–197, https://doi.org /10.2174/1568006043336302.
  16. Gimbrone M.A., García-Cardeña G. Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Cardiovasc Pathol 22(1): 9–15, https://doi. org/10.1016/j.carpath.2012.06.006.
  17. Corti R., Fuster V. Imaging of atherosclerosis: magnetic resonance imaging. Eur Heart J 2011; 32(14): 1709–1719, https://doi.org/10.1093/eurheartj/ehr068.
  18. Tabas I., Williams K.J., Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007; 116(16): 1832–1844, https://doi.org/10. 1161/circulationaha.106.676890.
  19. Nielsen L.B., Gronholdt M.L.M., Schroeder T.V., Stender S., Nordestgaard B.G. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol 1997; 17(5): 905–911, https://d oi.org/10.1161/01.atv.17.5.905.
  20. Bartels E.D., Christoffersen C., Lindholm M.W., Nielsen L.B. Altered metabolism of LDL in the arterial wall precedes atherosclerosis regression novelty and significance. Circ Res 2015; 117(11): 933–942, https://doi .org/10.1161/circresaha.115.307182.
  21. Nordestgaard B.G., Tybjaerg-Hansen A., Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler Thromb 1992; 12(1): 6–18, https://doi.or g/10.1161/01.atv.12.1.6.
  22. Donnelly L.H., Bree M.P., Hunter S.E., Keith J.C. Jr., Schaub R.G. Immunoreactive macrophage colony-stimulating factor is increased in atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits after recombinant human macrophage colony-stimulating factor therapy. Mol Reprod Dev 1997; 46(1): 92–95, https://doi.org/10.1002/(sici)10 98-2795(199701)46:192::aid-mrd143.0.co;2-5.
  23. Shi W., Wang X., Shih D.M., Laubach V.E., Navab M., Lusis A.J. Paradoxical reduction of fatty streak formation in mice lacking endothelial nitric oxide synthase. Circulation 2002; 105(17): 2078–2082, https://doi.org/10.1161/01 .cir.0000015853.59427.32.
  24. Poulsen C.B., Al-Mashhadi A.L., von Wachenfeldt K., Bentzon J.F., Nielsen L.B., Al-Mashhadi R.H., Thygesen J., Tolbod L., Larsen J.R., Frøkiær J., Tawakol A., Vucic E., Fredrickson J., Baruch A., Frendéus B., Robertson A.K., Moestrup S.K., Drouet L., Falk E. Treatment with a human recombinant monoclonal IgG antibody against oxidized LDL in atherosclerosis-prone pigs reduces cathepsin S in coronary lesions. Inter J Cardiology 2016; 215: 506–515, https://do i.org /10.1016/j.ijcard.2016.03.222.
  25. Salonen J.T., Ylä-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssönen K., Palinski W., Witztum J.L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339(8798): 883–887, https://doi.org/10.1016/0140-6736(9 2)90926-t.
  26. Bergmark C., Wu R., de Faire U., Lefvert A.K., Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 1995; 15(4): 441–445, https://doi.o rg/10.1161/01.atv.15.4.441.
  27. Shogenova M.H., Zhetisheva R.A., Karpov A.M., Dotsenko Y.V., Masenko V.P., Naumov V.G. The role of oxidized low-density lipoproteins and antibodies against oxidized low-density lipoproteins in the immune and inflammatory process in atherosclerosis. Ateroskleroz i dislipidemii 2015; 2: 17–21.
  28. Michelsen K.S., Arditi M. Toll-like receptor signaling and atherosclerosis. Curr Opin Hematol 2006; 13(3): 163–168, https://doi.org/10.1 097/01.moh.0000219662.88409.7c.
  29. Stoll G., Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006; 37(7): 1923–1932, https:/ /doi.org/10.1161/01.str.0000226901.34927.10.
  30. Groyer É., Caligiuri G., Laschet-Khallou J., Nicoletti A. Immunological aspects of atherosclerosis. Presse Med 2006; 35(3Pt 2): 475–486, https://doi.o r g/10.1016/s0755-4982(06)74622-x.
  31. Rajendran P., Rengarajan T., Thangavel J., Nishigaki Y., Sakthisekaran D., Sethi G., Nishigaki I. The vascular endothelium and human diseases. Int J Biol Sci 2013; 9(10): 1057–1069, https://doi.org/1 0.7150/ijbs.7502.
  32. Kalinin R.E., Gryaznov S.V., Nikiforov A.A., Kamaev A.A., Shvalb A.P., Slepnev A.A. Nitric oxide synthase and endothelin-1 gene polymorphism in lower limb chronic venous insufficiency. I.P. Pavlov Russian Medical Biological Herald 2015; 23(4): 97,https://doi.org/10.17816/pavl ovj2015497-102.
  33. Dow C.A., Templeton D.L., Lincenberg G.M., Greiner J.J., Stauffer B.L., DeSouza C.A. Elevations in C-reactive protein and endothelin-1 system activity in humans. Life Sci 2016; 159: 66–70, https://doi.org/10.101 6/j.lfs.2015.12.030.
  34. Trinity J.D., Barrett-O’Keefe Z., Ives S.J., Morgan G., Rossman M.J., Donato A.J., Runnels S., Morgan D.E., Gmelch B.S., Bledsoe A.D., Richardson R.S., Wray D.W. Endogenous endothelin-1 and femoral artery shear rate: impact of age and implications for atherosclerosis. J Hypertens 2016; 34(2): 266–273, https://doi.org/10.1097/hjh.0000000000000777 .
  35. Shelest B.A. Peripheral vessel wall changes in hypertensive patients with gout. Ter Arkh 2016; 88(5): 43–46, https://doi.org/10.17116/terark h201688543-46.
  36. Pavlides S., Gutierrez-Pajares J.L., Katiyar S., Jasmin J.F., Mercier I., Walters R., Pavlides C., Pestell R.G., Lisanti M.P., Frank P.G. Caveolin-1 regulates the anti-atherogenic properties of macrophages. Cell Tissue Res 2014; 358(3): 821–831, https://doi.org/10.1007/s00441-014-2008-4.
  37. Zborovskaya I.B., Galetskiy S.A., Komel’kov A.V. Microdomain forming proteins in oncogenesis. Uspekhi molekulyarnoy onkologii 2016; 3(3): 16–29.
  38. Engelberger R.P., Limacher A., Kucher N., Baumann F., Silbernagel G., Benghozi R., Do D.D., Willenberg T., Baumgartner I. Biological variation of established and novel biomarkers for atherosclerosis: results from a prospective, parallel-group cohort study. Clin Chim Acta 2015; 447: 16–22, https://doi.org/10.1016/j.cca.2015.05.003.
  39. Rozenberg I., Sluka S.H., Mocharla P., Hallenberg A., Rotzius P., Borén J., Kränkel N., Landmesser U., Borsig L., Lüscher T.F., Eriksson E.E., Tanner F.C. Deletion of L-selectin increases atherosclerosis development in ApoE–/– mice. PLoS One 2011; 6(7): e21675, https://doi.org/10.1371/journal.pone.0021675.
  40. Skopec I.S., Vezikova N.N., Marusenko I.M., Barysheva O.Y., Malafeev A.V., Malygin A.N. Correlation of inflammation biomarkers with the traditional risk factors in patients with acute coronary syndrome. Rational Pharmacotherapy in Cardiology 2016; 12(2): 166–170, https://doi.org/10.20996/1819-6446-2016-12-2-166-170.
  41. Galkina E., Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27(11): 2292–2301, https://doi.org/10.1161/atvbaha.107.149179.
  42. Kitagawa K., Matsumoto M., Sasaki T., Hashimoto H., Kuwabara K., Ohtsuki T., Hori M. Involvement of ICAM-1 in the progression of atherosclerosis in APOE-knockout mice. Atherosclerosis 2002; 160(2): 305–310, https://doi.org/10.1016/s0021-9150(01)00587-1.
  43. Signorelli S.S., Anzaldi M., Libra M., Navolanic P.M., Malaponte G., Mangano K., Quattrocchi C., Di Marco R., Fiore V., Neri S. Plasma levels of inflammatory biomarkers in peripheral arterial disease: results of a cohort study. Angiology 2016; 67(9): 870–874, https://doi.org/10.1177/0003319716633339.
  44. Belokopytova I.S., Moskaletz O.V., Paleev F.N., Zotova O.V. The diagnostic value of adhesive molecules sICAM-1 and sVCAM-1 in ischemic heart disease. Ateroskleroz i dislipidemii 2013; 4(12): 62–65.
  45. Circulation research thematic synopsis: atherosclerosis. Circ Res 2013; 112(10): e118–e147, https://doi.org/10.1161/circresaha.113.301487.
  46. Al-Ghurabi M.E., Muhi A.A., Al-Mudhafar D.H. Vascular cell adhesion molecule-1 and endothelial leukocyte adhesion molecule-1 as markers of atherosclerosis of NIDDM. American Journal of Life Sciences 2015; 3(1): 22–26, https://doi.org/10.11648/j.ajls.20150301.15.
  47. Bala G., Blykers A., Xavier C., Descamps B., Broisat A., Ghezzi C., Fagret D., Van Camp G., Caveliers V., Vanhove C., Lahoutte T., Droogmans S., Cosyns B., Devoogdt N., Hernot S. Targeting of vascular cell adhesion molecule-1 by 18F-labelled nanobodies for PET/CT imaging of inflamed atherosclerotic plaques. Eur Heart J Cardiovasc Imaging 2016; 17(9): 1001–1008, https://doi.org/10.1093/ehjci/jev346.
  48. Ni W., Egashira K., Kitamoto S., Kataoka C., Koyanagi M., Inoue S., Imaizumi K., Akiyama C., Nishida K.I., Takeshita A. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 2001; 103(16): 2096–2101, https://doi.org/10.1161/01.cir.103.16.2096.
  49. Tsai M.K., Hsieh C.C., Kuo H.F., Lee M.S., Huang M.Y., Kuo C.H., Hung C.H. Effect of prostaglandin I2 analogs on monocyte chemoattractant protein-1 in human monocyte and macrophage. Clin Exp Med 2015; 15(3): 245–253, https://doi.org/10.1007/s10238-014-0304-7.
  50. Kim C.H., Mitchell J.B., Bursill C.A., Sowers A.L., Thetford A., Cook J.A., van Reyk D.M., Davies M.J. The nitroxide radical TEMPOL prevents obesity, hyperlipidaemia, elevation of inflammatory cytokines, and modulates atherosclerotic plaque composition in apoE–/– mice. Atherosclerosis 2015; 240(1): 234–241, https://doi.org/10.1016/j.atherosclerosis.2015.03.012.
  51. Saitoh T., Kishida H., Tsukada Y., Fukuma Y., Sano J., Yasutake M., Fukuma N., Kusama Y., Hayakawa H. Clinical significance of increased plasma concentration of macrophage colony-stimulating factor in patients with angina pectoris. J Am Coll Cardiol 2000; 35(3): 655–665, https://doi.org/10.1016/s0735-1097(99)00583-5.
  52. Nozadze D.N., Rvacheva A.V., Kaznacheeva E.I., Sergienko I.V. Monocytes in the development and destabilization of atherosclerotic plaques. Ateroskleroz i dislipidemii 2012; 3: 25–36.
  53. Cybulsky M.I., Cheong C., Robbins C.S. Macrophages and dendritic cells: partners in atherogenesis. Circ Res 2016; 118(4): 637–652, https://doi.org/10.1161/circresaha.115.306542.
  54. Seshiah P.N., Kereiakes D.J., Vasudevan S.S., Lopes N., Su B.Y., Flavahan N.A., Goldschmidt-Clermont P.J. Activated monocytes induce smooth muscle cell death: role of macrophage colony-stimulating factor and cell contact. Circulation 2002; 105(2): 174–180, https://doi.org/10.1161/hc0202.102248.
  55. Lind L., Siegbahn A., Lindahl B., Stenemo M., Sundström J., Ärnlöv J. Discovery of new risk markers for ischemic stroke using a novel targeted proteomics chip. Stroke 2015; 46(12): 3340–3347, https://doi.org/10.1161/strokeaha.115.010829.
  56. Andrés V., Pello O.M., Silvestre-Roig C. Macrophage proliferation and apoptosis in atherosclerosis. Curr Opin Lipidol 2012; 23(5): 429–438, https://doi.org/10.1097/mol.0b013e328357a379.
  57. Kan X.H., Zhong X.Z., Zhang W.D., Shi C.Y. Increased circulating macrophage-colony stimulating factor and monocyte chemoattractant protein-1 are predictors of in-hospital events in Chinese patients with unstable angina pectoris. Int J Clin Exp Pathol 2016; 9(2): 2021–2026.
  58. Brånén L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004; 24(11): 2137–2142, https://doi.org/10.1161/01.atv.0000143933.20616.1b.
  59. Ohta H., Wada H., Niwa T., Kirii H., Iwamoto N., Fujii H., Saito K., Sekikawa K., Seishima M. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005; 180(1): 11–17, https://doi.org/10.1016/j.atherosclerosis.2004.11.016.
  60. Kober F., Canault M., Peiretti F., Mueller C., Kopp F., Alessi M.C., Cozzone P.J., Nalbone G., Bernard M. MRI follow-up of TNF-dependent differential progression of atherosclerotic wall-thickening in mouse aortic arch from early to advanced stages. Atherosclerosis 2007; 195(2): e93–e99, https://doi.org/10.1016/j.atherosclerosis.2007.06.015.
  61. Chew M., Zhou J., Daugherty A., Eriksson T., Ellermann-Eriksen S., Hansen P.R., Falk E. Thalidomide inhibits early atherogenesis in apoE-deficient mice. APMIS Suppl 2003; 109: 113–116.
  62. Boesten L.S., Zadelaar A.S., van Nieuwkoop A., Gijbels M.J., de Winther M.P., Havekes L.M., van Vlijmen B.J. Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-Leiden transgenic mice. Cardiovasc Res 2005; 66(1): 179–185, https://doi.org/10.1016/j.cardiores.2005.01.001.
  63. Canault M., Peiretti F., Mueller C., Kopp F., Morange P., Rihs S., Portugal H., Juhan-Vague I., Nalbone G. Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis 2004; 172(2): 211–218, https://doi.org/10.1016/j.atherosclerosis.2003.10.004.
  64. Prasad S., Tyagi A.K., Aggarwal B.B. Detection of inflammatory biomarkers in saliva and urine: potential in diagnosis, prevention, and treatment for chronic diseases. Exp Biol Med 2016; 241(8): 783–799, https://doi.org/10.1177/1535370216638770.
  65. Weintraub W.S., Harrison D.G. C-reactive protein, inflammation and atherosclerosis: do we really understand it yet? Eur Heart J 2000; 21(12): 958–960, https://doi.org/10.1053/euhj.2000.2109.
  66. Libby P., Ridker P.M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004; 116(Suppl 6A): 9S–16S, https://doi.org/10.1016/j.amjmed.2004.02.006.
  67. Ikonomidis I., Lekakis J., Revela I., Andreotti F., Nihoyannopoulos P. Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease. Eur Heart J 2005; 26(16): 1618–1624, https://doi.org/10.1093/eurheartj/ehi192.
  68. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol 2013; 168(6): 5126–5134, https://doi.org/10.1016/j.ijcard.2013.07.113.
  69. Yu Q., Liu Z., Waqar A.B., Ning B., Yang X., Shiomi M., Graham M.J., Crooke R.M., Liu E., Dong S., Fan J. Effects of antisense oligonucleotides against C-reactive protein on the development of atherosclerosis in WHHL rabbits. Mediators Inflamm 2014; 2014: 979132, https://doi.org/10.1155/2014/979132.
  70. Cossette É., Cloutier I., Tardif K., DonPierre G., Tanguay J.F. Estradiol inhibits vascular endothelial cells pro-inflammatory activation induced by C-reactive protein. Mol Cell Biochem 2013; 373(1–2): 137–147, https://doi.org/10.1007/s11010-012-1482-9.
  71. Wang Q., Huo L., He J., Ding W., Su H., Tian D., Welch C., Hammock B.D., Ai D., Zhu Y. Soluble epoxide hydrolase is involved in the development of atherosclerosis and arterial neointima formation by regulating smooth muscle cell migration. Am J Physiol Heart Circ Physiol 2015; 309(11): H1894–H1903, https://doi.org/10.1152/ajpheart.00289.2015.
  72. Wu M.D., Atkinson T.M., Lindner J.R. Platelets and von Willebrand factor in atherogenesis. Blood 2017; 129(11): 1415–1419, https://doi.org/10.1182/blood-2016-07-692673.
  73. Ricci C., Ferri N. Naturally occurring PDGF receptor inhibitors with potential anti-atherosclerotic properties. Vascul Pharmacol 2015; 70: 1–7, https://doi.org/10.1016/j.vph.2015.02.002.
  74. Lee M.H., Kwon B.-J., Koo M.-A., You K.E., Park J.-C. Mitogenesis of vascular smooth muscle cell stimulated by platelet-derived growth factor-bb is inhibited by blocking of intracellular signaling by epigallocatechin-3-O-gallate. Oxid Med Cell Longev 2013; 2013: 827905, https://doi.org/10.1155/2013/827905.
  75. Sihvola R. Platelet-derived growth factor and proinflammatory cytokines in cardiac allograft arteriosclerosis. Academic Dissertation. Helsinki; 2003.
  76. Heldin C.H., Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79(4): 1283–1316.
  77. Pope C.A., Bhatnagar A., McCracken J.P., Abplanalp W., Conklin D.J., O’Toole T. Exposure to fine particulate air pollution is associated with endothelial injury and systemic inflammation novelty and significance. Circ Res 2016; 119(11): 1204–1214, https://doi.org/10.1161/circresaha.116.309279.
  78. Chi H., Messas E., Levine R.A., Graves D.T., Amar S. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein e heterozygote model: pharmacotherapeutic implications. Circulation 2004; 110(12): 1678–1685, https://doi.org/10.1161/01.cir.0000142085.39015.31.
  79. von der Thüsen J.H., Kuiper J., van Berkel T.J., Biessen E.A. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 2003; 55(1): 133–166, https://doi.org/10.1124/pr.55.1.5.
  80. Vicenová B., Vopálenský V., Burýsek L., Pospísek M. Emerging role of interleukin-1 in cardiovascular diseases. Physiol Res 2009; 58(4): 481–498, https://doi.org/10.1161/circresaha.115.304437.
  81. Folco E.J., Sukhova G.K., Quillard T., Libby P. Moderate hypoxia potentiates interleukin-1β production in activated human macrophages. Circ Res 2014; 115(10): 875–883, https://doi.org/10.1161/circresaha.115.304437.
  82. Pagano P.J., Gutterman D.D. The adventitia: the outs and ins of vascular disease. Cardiovasc Res 2007; 75(4): 636–639, https://doi.org/10.1016/j.cardiores.2007.07.006.
  83. Edsfeldt A., Grufman H., Asciutto G., Nitulescu M., Persson A., Nilsson M., Nilsson J., Gonçalves I. Circulating cytokines reflect the expression of pro-inflammatory cytokines in atherosclerotic plaques. Atherosclerosis 2015; 241(2): 443–449, https://doi.org/10.1016/j.atherosclerosis.2015.05.019.
  84. Young J.L., Libby P., Schönbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002; 88(4): 554–567.
  85. Nakai Y., Iwabuchi K., Fujii S., Ishimori N., Dashtsoodol N., Watano K., Mishima T., Iwabuchi C., Tanaka S., Bezbradica J.S., Nakayama T., Taniguchi M., Miyake S., Yamamura T., Kitabatake A., Joyce S., Van Kaer L., Onoé K. Natural killer T cells accelerate atherogenesis in mice. Blood 2004; 104(7): 2051–2059, https://doi.org/10.1182/blood-2003-10-3485.
  86. Aslanian A.M., Chapman H.A., Charo I.F. Transient role for CD1d-restricted natural killer T cells in the formation of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2005; 25(3): 628–632, https://doi.org/10.1161/01.atv.0000153046.59370.13.
  87. Voloshyna I., Littlefield M.J., Reiss A.B. Atherosclerosis and interferon-γ: new insights and therapeutic targets. Trends Cardiovasc Med 2014; 24(1): 45–51, https://doi.org/10.1016/j.tcm.2013.06.003.
  88. Harvey E., Ramji D. Interferon-γ and atherosclerosis: pro- or anti-atherogenic? Cardiovasc Res 2005; 67(1): 11–20, https://doi.org/10.1016/j.cardiores.2005.04.019.
  89. Tavakoli N.N., Harris A.K., Sullivan D.R., Hambly B.D., Bao S. Interferon-γ deficiency reduces neointimal formation in a model of endoluminal endothelial injury combined with atherogenic diet. Int J Mol Med 2012; 30(3): 545–552, https://doi.org/10.3892/ijmm.2012.1034.
  90. Kunjathoor V.V., Febbraio M., Podrez E.A., Moore K.J., Andersson L., Koehn S., Rhee J.S., Silverstein R., Hoff H.F., Freeman M.W. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002; 277(51): 49982–49988, https://doi.org/10.1074/jbc.m209649200.
  91. Febbraio M., Podrez E.A., Smith J.D., Hajjar D.P., Hazen S.L., Hoff H.F., Sharma K., Silverstein R.L. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105(8): 1049–1056, https://doi.org/10.1172/jci9259.
  92. Rigotti A. Scavenger receptors and atherosclerosis. Biol Res 2000; 33(2): 97–103, https://doi.org/10.4067/s0716-97602000000200009.
  93. Mrochek A.G., Stel’mashok V.I., Adzerikho I.E., Savchuk A.I., Avdey P.P. A case of a successful restoration of limb blood supply by percutaneous ultrasound angioplasty in a patient with obliterating atherosclerosis of the left superficial femoral artery. Angiologiya i sosudistaya khirurgiya 2002; 8(1): 100–104.
  94. Alekyan B.G., Dubrovskiy V.A., Stepanov A.D., Filatov E.N., Khazov I.A. Sredstvo dlya podderzhaniya prosveta sosuda ili pologo organa [An agent to maintain a lumen of a vessel or a hollow organ]. Patent RU 2169544. 2001.
  95. Karpov D.A., Kochanov I.N., Kislov I.F., Mazaev S.N., Samko A.N., Sukhov V.K. Vnutrisosudistyy protez dlya vosstanovleniya i/ili sokhraneniya prosveta krovenosnogo sosuda (varianty) [Intravascular prosthesis for blood vessel recanalization and/or maintenance (variants)]. Patent RU 2253410. 2005.
  96. Tu J.V., Wang H., Bowyer B., Green L., Fang J., Kucey D.; Participants in the Ontario Carotid Endarterectomy Registry. Risk factors for death or stroke after carotid endarterectomy: observations from the Ontario Carotid Endarterectomy Registry. Stroke 2003; 34(11): 2568–1573, https://doi.org/10.1161/01.str.0000092491.45227.0f.
  97. L’Heureux N., Dusserre N., Konig G., Victor B., Keire P., Wight T.N., Chronos N.A., Kyles A.E., Gregory C.R., Hoyt G., Robbins R.C., McAllister T.N. Human tissue-engineered blood vessels for adult arterial revascularization. Nat Med 2006; 12(3): 361–365, https://doi.org/10.1038/nm1364.
  98. Spiridonov A.A., Morozov K.M., Fedorovich A.A. Sposob khirurgicheskogo lecheniya khronicheskoy kriticheskoy ishemii nizhnikh konechnostey [A surgical modality of chronic critical lower limb ischemia]. Patent RU 2206274. 2003.
  99. Troitsky A.V., Lysenko Ye.R., Khabazov R.I., Orekhov P.Yu., Parshin P.Yu., Korolev V.I., Ustyantseva N.V., Malyutina Ye.D., Nishchenko A.V. Results of primary reconstructions in patients with lesion of the tibial arteries. Angiologiya i sosudistaya khirurgiya 2003; 9(1): 102–108.
  100. Mumladze R.B., Nartov A.P. Sposob lecheniya bol’nykh s khronicheskoy arterial’noy nedostatochnost’yu nizhnikh konechnostey [A treatment modality for patients with chronic arterial insufficiency of lower limbs]. Patent RU 2162356. 2001.
  101. Suchkova Zh.V., Byalovskiy Yu.Yu., Morozov V.N., Khadartsev A.A. Sposob lecheniya ateroskleroticheskikh porazheniy sosudov nizhnikh konechnostey [A treatment modality of arterial sclerotic disease of lower limb vessels]. Patent RF 2261734. 2005.
  102. Natsional’nye rekomendatsii po vedeniyu patsientov s zabolevaniyami arteriy nizhnikh konechnostey. Rossiyskiy soglasitel’nyy document [National guidelines on managing patients with lower limb arterial diseases. Russian conciliation document]. Moscow; 2013.
  103. Bolshakov I.N., Dolgikh O.A., Kirichenko A.K., Kotikov A.R., Gorbunova V.O. Wall vessel reconstruction in atherogenesis using chitosan biopolymers. Fundamental’nye issledovaniya 2009; S7: 42–43.
  104. Dolgih O.A., Gorbunova V.O. Experimental justification of natural biopolymers reconstruction of magistral arteries in low extremities in case of modeled atherogenesis. Sibirskoe meditsinskoe obozrenie 2009; 3(57): 88–90.
  105. Kotikov A.R., Dolgikh O.A., Gorbunova V.O., Bolshakov I.N., Zykova L.D. Morfometriya sosudov nizhnikh konechnostey posle maloinvazivnoy rekonstruktsii sul’fatirovannym proizvodnym khitozana pri eksperimental’nom aterogeneze. V kn.: Materialy X Mezhdunarodnoy konferentsii “Sovremennye perspektivy v issledovanii khitina i khitozana” [Lower limb vessel morphometry after minimally invasive reconstruction by sulphated chitosan derivative in experimental atherogenesis. In: Proceedings of X International conference “Modern prospects in chitin and chitosan studies”]. Nizhny Novgorod; 2010; p. 204–207.
  106. Bolshakov I.N., Shestakova L.A., Kirichenko A.K., Ali-Riza A.E., Kotikov A.R., Dolgikh O.A., Gorbunova V.O. Maloinvazivnaya tekhnologiya angiogeneza pri rekonstruktsii stenki magistral’nykh sosudov nizhnikh konechnostey v eksperimente. V kn.: Tezisy dokladov III Mezhdunarodnoy konferentsii “Sovremennye tekhnologii i vozmozhnosti rekonstruktivno-vosstanovitel’noy i esteticheskoy khirurgii” [A minimally invasive angiogenesis technology in lower limb great vessel wall reconstruction in experiment. In: Abstracts of III International conference “Modern technologies and capabilities of reconstructive and esthetic surgery”]. Moscow; 2012; p. 59–61.
  107. Bolshakov I.N., Shestakova L.A., Kotikov A.R. Maloinvazivnaya tekhnologiya angiogeneza pri rekonstruktsii stenki magistral’nykh sosudov nizhnikh konechnostey v eksperimente. V kn.: Materialy regional’noy nauchno-prakticheskoy konferentsii “Aktual’nye voprosy abdominal’noy i sosudistoy khirurgii” [A minimally invasive angiogenesis technology in lower limb great vessel wall reconstruction in experiment. In: Proceedings of regional research and practice conference “Urgent issues of abdominal and vascular surgery”]. Barnaul; 2012; p. 96–97.
  108. Polignano R., Baggiore C., Falciani F., Restelli U., Troisi N., Michelagnoli S., Panigada G., Tatini S., Farina A., Landini G. Efficacy, safety and feasibility of intravenous iloprost in the domiciliary treatment of patients with ischemic disease of the lower limbs. Eur Rev Med Pharmacol Sci 2016; 20(17): 3720–3726.
  109. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G.R. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33(1): S1–S75, https://doi.org/10.1016/j.ejvs.2006.09.024.
  110. Meini S., De Franco V., Auteri A., Setacci C., Di Renzo M., Pieragalli D. Short-term and long-term effects of one-week treatment with intravenous iloprost in critical limb ischemia patients (Leriche-Fontaine stage III and IV). Int Angiol 2005; 24(1): 64–69.
  111. Gavrilenko A.V., Kotov A.E., Loikov D.A. Surgical treatment of critical lower limb ischemia in diabetic patients. Annaly khirurgii 2012; (2): 10–15.
  112. Pels K., Deiner C., Coupland S.E., Noutsias M., Sutter A.P., Schultheiss H.P., Yla-Herttuala S., Schwimmbeck P.L. Effect of adventitial VEGF(165) gene transfer on vascular thickening after coronary artery balloon injury. Cardiovasc Res 2003; 60(3): 664–672, https://doi.org/10.1016/j.cardiores.2003.09.003.
  113. Skóra J., Barć P., Dawiskiba T., Baczyńska D., Mastalerz-Migas A. Angiogenesis after plasmid VEGF165 gene transfer in an animal model. Cent Eur J Immunol 2013; 3: 305–309, https://doi.org/10.5114/ceji.2013.37751.
  114. Deev R.V., Kalinin R.E., Chervyakov Y.V., Gryaznov S.G., Mzhavanadze N.D., Kiselev S.L., Isaev A.A., Schwalb P.G., Staroverov I.N., Nersessian E.G. Results of gen-therapeutic drug “Neovasculgen” in patients with chronic lower limb ischemia: 1 year of observation. Vestnik Natsional’nogo mediko-khirurgicheskogo Tsentra im. N.I. Pirogova 2011; 6(4): 20–25.
  115. Chervyakov Yu.V., Staroverov I.N., Vlasenko O.N., Nersesyan E.G., Isaev A.A., Deev R.V. Remote results of treatment of patients with chronic lower-limb ischaemia by means of indirect revascularization and gene therapy. Angiologiya i sosudistaya khirurgiya 2016; 22(1): 29–37.
  116. Deev R.V., Grigoryan A.S., Potapov I.V., Kiselev S.L., Isaev A.A. Worldwide experience and recent trends in gene therapy of ischaemic diseases. Angiologiya i sosudistaya khirurgiya 2011; 17(2): 145–154.
  117. Shval’b P.G., Gavrilenko A.V., Kalinin R.E., Chervyakov Yu.V., Voronov D.A., Staroverov I.N., Gryaznov S.V., Mzhavanadze N.D., Nersesyan E.G., Kiselev S.L., Isaev A.A., Deev R.V. Efficacy and safety of application “Neovasculgen” in the complex treatment patients with chronic lower limb ischemia (IIb-III phase of clinical trials). Kletochnaya transplantologiya i tkanevaya inzheneriya 2011; 6(3): 76–83.
  118. Kalinin R.E., Suchkov I.A., Pshennikov A.S., Mzhavanadze N.D., Krylov A.A., Plaksa I.L., Deev R.V. Efficacy of medication for therapeutic angiogenesis in combined treatment of patients with diabetes mellitus and critical limb ischemia. Kazanskiy meditsinskiy zhurnal 2016; 97(5): 674–680. https://doi.org/10.17750/kmj2016-674.
  119. Kalinin R.E., Suchkov I.A., Mzhavanadze N.D., Krylov A.A., Plaksa I.L., Deev R.V. Experience of using gene therapy technologies in the management of patients with advanced peripheral atherosclerosis and severe diabetes mellitus. Angiologiya i sosudistaya khirurgiya 2016; 22(S2): 140–141.
  120. Deev R.V., Plaksa I.L., Bozo I.Y., Isaev A.A. Long-term 5 years follow-up gene therapy for peripheral arterial disease. Human Gene Therapy 2016; 27(5): A101–A102.
  121. Yudin M.A., Plaksa I.L., Mzhavanadze N.D., Krakovskii M.A., Bykov V.N., Mavlikeev M.O., Isaev A.A., Kalinin R.E., Deev R.V. Estimation of systemic distribution and angiogenic effect of pl-VEGF165 in the model of limb ischemia. Patologiya krovoobrashcheniya i kardiokhirurgiya 2015; 19(S4–2): 33–42.
  122. Belousov E.Yu., Soroka V.V., Nochrin S.P., Ryazanov A.N. Experience of aniogenic therapy in the treatment of patients with chronic lower limb ischemia. Trudnyy patsient 2014; 12(10): 40–43.
  123. Kleemann R., Zadelaar S., Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008; 79(3): 360–376, https://doi.org/10.1093/cvr/cvn120.
  124. Poredos P., Jezovnik M.K. The role of inflammatory biomarkers in the detection and therapy of atherosclerotic disease. Curr Vasc Pharmacol 2016; 14(6): 534–546, https://doi.org/10.2174/1570161114666160625080104.
  125. Kim S., Kawai T., Wang D., Yang Y. Engineering a dual-layer chitosan-lactide hydrogel to create endothelial cell aggregate-induced microvascular networks in vitro and increase blood perfusion in vivo. ACS Appl Mater Interfaces 2016; 8(30): 19245–19255, https://doi.org/10.1021/acsami.6b04431.
  126. Lee S., Valmikinathan C.M., Byun J., Kim S., Lee G., Mokarram N., Pai S.B., Um E., Bellamkonda R.V., Yoon Y.S. Enhanced therapeutic neovascularization by CD31-expressing cells and embryonic stem cell-derived endothelial cells engineered with chitosan hydrogel containing VEGF-releasing microtubes. Biomaterials 2015; 63: 158–167, https://doi.org/10.1016/j.biomaterials.2015.06.009.
  127. Auger F.A., D’Orléans-Juste P., Germain L. Adventitia contribution to vascular contraction: hints provided by tissue-engineered substitutes. Cardiovasc Res 2007; 75(4): 669–678, https://doi.org/10.1016/j.cardiores.2007.06.001.
  128. Laflamme K., Roberge C.J., Grenier G., Rémy-Zolghadri M., Pouliot S., Baker K., Labbé R., D’Orléans-Juste P., Auger F.A., Germain L. Adventitia contribution in vascular tone: insights from adventitia-derived cells in a tissue-engineered human blood vessel. FASEB J 2006; 20(8): 1245–1247, https://doi.org/10.1096/fj.05-4702fje.
  129. Herrmann J., Lerman L.O., Rodriguez-Porcel M., Holmes D.R. Jr., Richardson D.M., Ritman E.L., Lerman A. Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. Cardiovasc Res 2001; 51(4): 762–766, https://doi.org/10.1016/s0008-6363(01)00347-9.
  130. Han Y., Runge M.S., Brasier A.R. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 1999; 84(6): 695–703, https://doi.org/10.1161/01.res.84.6.695.
  131. Ni W., Kitamoto S., Ishibashi M., Usui M., Inoue S., Hiasa K., Zhao Q., Nishida K., Takeshita A., Egashira K. Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2004; 24(3): 534–539, https://doi.org/10.1161/01.atv.0000118275.60121.2b.
  132. Chan E.C., Datla S.R., Dilley R., Hickey H., Drummond G.R., Dusting G.J. Adventitial application of the NADPH oxidase inhibitor apocynin in vivo reduces neointima formation and endothelial dysfunction in rabbits. Cardiovasc Res 2007; 75(4): 710–718, https://doi.org/10.1016/j.cardiores.2007.06.005.
  133. Potter C.M., Lao K.H., Zeng L., Xu Q. Role of biomechanical forces in stem cell vascular lineage differentiation. Arterioscler Thromb Vasc Biol 2014; 34(10): 2184–2190, https://doi.org/10.1161/atvbaha.114.303423.
  134. Rey F.E., Pagano P.J. The reactive adventitia: fibroblast oxidase in vascular function. Arterioscler Thromb Vasc Biol 2002; 22(12): 1962–1971, https://doi.org/10.1161/01.atv.0000043452.30772.18.
  135. Soto-Gutierrez A., Yagi H., Uygun B.E., Navarro-Alvarez N., Uygun K., Kobayashi N., Yang Y.G., Yarmush M.L. Cell delivery: from cell transplantation to organ engineering. Cell Transplant 2010; 19(6): 655–665, https://doi.org/10.3727/096368910x508753.
  136. Nugent H.M., Rogers C., Edelman E.R. Endothelial implants inhibit intimal hyperplasia after porcine angioplasty. Circ Res 1999; 84(4): 384–391, https://doi.org/10.1161/01.res.84.4.384.
  137. Nugent H.M., Groothuis A., Seifert P., Guerraro J.L., Nedelman M., Mohanakumar T., Edelman E.R. Perivascular endothelial implants inhibit intimal hyperplasia in a model of arteriovenous fistulae: a safety and efficacy study in the pig. J Vasc Res 2002; 39(6): 524–533, https://doi.org/10.1159/000067207.
  138. Nugent H.M., Sjin R.T., White D., Milton L.G., Manson R.J., Lawson J.H., Edelman E.R. Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts. J Vasc Surg 2007; 46(3): 548–556, https://doi.org/10.1016/j.jvs.2007.04.074.
  139. van der Valk F.M., Kuijk C., Verweij S.L., Stiekema L.C.A., Kaiser Y., Zeerleder S., Nahrendorf M., Voermans C., Stroes E.S.G. Increased haematopoietic activity in patients with atherosclerosis. Eur Heart J 2017; 38(6): 425–432, https://doi.org/10.1093/eurheartj/ehw246.
  140. Van der Veken B., De Meyer G.R., Martinet W. Intraplaque neovascularization as a novel therapeutic target in advanced atherosclerosis. Expert Opin Ther Targets 2016; 20(10): 1247–1257, https://doi.org/10.1080/14728222.2016.1186650.
  141. Suzuki J., Shimamura M., Suda H., Wakayama K., Kumagai H., Ikeda Y., Akazawa H., Isobe M., Komuro I., Morishita R. Current therapies and investigational drugs for peripheral arterial disease. Hypertens Res 2016; 39(4): 183–191, https://doi.org/10.1038/hr.2015.134.
  142. Liu M.H., Tang Z.H., Li G.H., Qu S.L., Zhang Y., Ren Z., Liu L.S., Jiang Z.S. Janus-like role of fibroblast growth factor 2 in arteriosclerotic coronary artery disease: atherogenesis and angiogenesis. Atherosclerosis 2013; 229(1): 10–17, https://doi.org/10.1016/j.atherosclerosis.2013.03.013.
  143. Braghirolli D.I., Helfer V.E., Chagastelles P.C., Dalberto T.P., Gamba D., Pranke P. Electrospun scaffolds functionalized with heparin and vascular endothelial growth factor increase the proliferation of endothelial progenitor cells. Biomed Mater 2017; 12(2): 025003, https://doi.org/10.1088/1748-605x/aa5bbc.
  144. Kaplanskaya I.B., Glasko E.N., Frank G.A. Angiogenesis, intercellular contacts and stromal-parenchimatous relationships in health and disease. Rossiyskiy onkologicheskiy zhurnal 2005; 4: 53–57.
  145. Gavrilenko T.I., Ryzhkova N.A., Parkhomenko A.N. Vascular endothelial growth factor in the clinic of internal diseases and its pathogenetic value. Ukrai’ns’kyj kardiologichnyj zhurnal 2011; 4: 87–95.
  146. Hoeben A., Landuyt B., Highley M.S., Wildiers H., Van Oosterom A.T., De Bruijn E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004; 56(4): 549–580, https://doi.org/10.1124/pr.56.4.3.
  147. Barc P., Plonek T., Baczynska D., Radwanska A., Witkiewicz W., Halon A., Kupczynska-Markiewicz D., Strozecki L., Korta K., Skora J. A combination of VEGF165/HGF genes is more effective in blood vessels formation than ANGPT1/VEGF165 genes in an in vivo rat model. Int J Clin Exp Med 2016; 9(7): 12737–12744.
  148. Makarevich P.I., Boldyreva M.A., Gluhanyuk E.V., Efimenko A.Y., Dergilev K.V., Shevchenko E.K., Sharonov G.V., Gallinger J.O., Rodina P.A., Sarkisyan S.S., Hu Y.C., Parfyonova Y.V. Enhanced angiogenesis in ischemic skeletal muscle after transplantation of cell sheets from baculovirus-transduced adipose-derived stromal cells expressing VEGF165. Stem Cell Res Ther 2015; 6: 204, https://doi.org/10.1186/s13287-015-0199-6.
  149. Vemulapalli S., Patel M.R., Jones W.S. Limb ischemia: cardiovascular diagnosis and management from head to toe. Curr Cardiol Rep 2015; 17(7): 611, https://doi.org/10.1007/s11886-015-0611-y.
  150. Cooke J.P., Losordo D.W. Modulating the vascular response to limb ischemia: angiogenic and cell therapies. Circ Res 2015; 116(9): 1561–1578, https://doi.org/10.1161/circresaha.115.303565.
  151. Lederman R.J., Mendelsohn F.O., Anderson R.D., Saucedo J.F., Tenaglia A.N., Hermiller J.B., Hillegass W.B., Rocha-Singh K., Moon T.E., Whitehouse M.J., Annex B.H.; TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359(9392): 2053–2058, https://doi.org/10.1016/s0140-6736(02)08937-7.
  152. Jazwa A., Florczyk U., Grochot-Przeczek A., Krist B., Loboda A., Jozkowicz A., Dulak J. Limb ischemia and vessel regeneration: is there a role for VEGF? Vascul Pharmacol 2016; 86: 18–30, https://doi.org/10.1016/j.vph.2016.09.003.
  153. Bokeriya L.A., Eremeeva M.V., Kiselev S.L., Arakelyan V.S., Demidova O.A., Makarenko V.N. Creation and experience of using a VEGF-based agent in the treatment of chronic lower limb ischemia. Kletochnaya transplantologiya i tkanevaya inzheneriya 2011; 6(1): 105.
  154. Gavrilenko A.V., Voronov D.A., Bochkov N.P. Angiogenesis stimulation in an integrated therapy of patients with chronic lower limb ischemia (combination of reconstructive surgeries and genetically engineering technologies). Kletochnaya transplantologiya i tkanevaya inzheneriya 2011; 6(1): 105–106.
  155. Deev R.V., Kiselev S.L., Isaev A.A., Prikhod’ko A.V., Potapov I.V. Global experience of gene therapy of chronic lower limb ischemia CHD. Kletochnaya transplantologiya i tkanevaya inzheneriya 2011; 6(1): 106.
  156. Staroverov I.N., Chervyakov Yu.V., Kuz’min R.N., Nersesyan E.G., Deev R.V. The treatment results of patients with chronic obliterating diseases of lower limb arteries by an agent based on a gene encoding vascular endothelial growth factor (VEGF). Kletochnaya transplantologiya i tkanevaya inzheneriya 2011; 6(1): 106–107.
  157. Shval’b P.G., Kalinin R.E., Gryaznov S.V. The experience of using an agent based on VEGF gene in patients with chronic obliterating lower limb diseases. Kletochnaya transplantologiya i tkanevaya inzheneriya 2011; 6(1): 107.
  158. Ding X., Gao J., Wang Z., Awada H., Wang Y. A shear-thinning hydrogel that extends in vivo bioactivity of FGF2. Biomaterials 2016; 111: 80–89, https://doi.org/10.1016/j.biomaterials.2016.09.026.
  159. Shahzadi L., Yar M., Jamal A., Siddiqi S.A., Chaudhry A.A., Zahid S., Tariq M., Rehman I.U., MacNeil S. Triethyl orthoformate covalently cross-linked chitosan-(poly vinyl) alcohol based biodegradable scaffolds with heparin-binding ability for promoting neovascularisation. J Biomater Appl 2016; 31(4): 582–593, https://doi.org/10.1177/0885328216650125.
  160. Yar M., Gigliobianco G., Shahzadi L., Dew L., Siddiqi S.A., Khan A.F., Chaudhry A.A., ur Rehman I., MacNeil S. Production of chitosan PVA PCL hydrogels to bind heparin and induce angiogenesis. International Journal of Polymeric Materials and Polymeric Biomaterials 2016; 65(9): 466–476, https://doi.org/10.1080/00914037.2015.1129959.
  161. Huang Y.C., Yang Y.T. Effect of basic fibroblast growth factor released from chitosan-fucoidan nanoparticles on neurite extension. J Tissue Eng Regen Med 2016; 10(5): 418–427, https://doi.org/10.1002/term.1752.
  162. Zhang J., Li G., Gao S., Yao Y., Pang L., Li Y., Wang W., Zhao Q., Kong D., Li C. Monocyte chemoattractant protein-1 released from polycaprolactone/chitosan hybrid membrane to promote angiogenesis in vivo. Journal of Bioactive and Compatible Polymers 2014; 29(6): 572–588, https://doi.org/10.1177/0883911514554146.

Kirichenko А.К., Patlataya N.N., Sharkova А.F., Pevnev А.А., Kontorev К.V., Shapovalova О.V., Gorban М.Е., Bolshakov I.N. Pathomorphism of Limb Major Vessels in Experimental Atherogenic Inflammation. The Role of Adventitial Intimal Relations (Review). Sovremennye tehnologii v medicine 2017; 9(3): 162, https://doi.org/10.17691/stm2017.9.3.20


Journal in Databases

pubmed_logo.jpg

web_of_science.jpg

scopus.jpg

crossref.jpg

ebsco.jpg

embase.jpg

ulrich.jpg

cyberleninka.jpg

e-library.jpg

lan.jpg

ajd.jpg

SCImago Journal & Country Rank

Publication is registered by Federal Service for Supervision in the Sphere of Telecom, Information Technologies and Mass Communications.
Mass Media Registration Certificate PE № FS 77-79187 dated October 16, 2020.

If reproducing any part of the publication a reference to the Journal is obligatory.